* denotes a publication that resulted from CTD2 intra-Network collaborations
Researchers present a cancer driver annotation (CanDrA) tool that predicts missense driver mutations based on a set of 95 structural and evolutionary features computed by over 10 functional prediction algorithms.
Researchers accrued a library of natural products and performed a screen to identify molecular targets.
Investigators use a high-throughput assay to identify genomic predictors of radiation sensitivity
Researchers document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner and clarify specific oncogenic signaling relationships in glioblastoma.
Author comment on Dual blockade of the PI3K/AKT/mTOR(AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergystically inhibits rhabdomyosarcoma...
A review on the role of MYCN and other newly identifed drivers in neuroblastoma.
A collaborative effort to compare the molecular changes across the original 12 tumor types profiled by The Cancer Genome Atlas.
Using a newly developed platform to identify the signaling pathway/molecular target of natural products, we identified a family of alkaloid natural products, discoipyrroles A-D (1-4), from Bacillus hunanensis that inhibit the DDR2 signaling pathway.
3q26 is frequently amplified in several cancer types with a common amplified region containing 20 genes. To identify cancer driver genes in this region, we interrogated the function of each of these genes.